| Similar Articles |
|---|
 |
The Motley Fool
November 2, 2011
David Williamson |
After Hours: Dendreon's Shares Crushed Again Bad guidance in third quarter earnings punishes this stock.   |
The Motley Fool
September 22, 2010
Brian Orelli |
A Dendreon Deal: It's Not What You Think Dendreon gets help manufacturing Provenge, but there's still work ahead. |
The Motley Fool
August 4, 2011
Brian Orelli |
Dendreon Down 65%! What's Next? What caused Dendreon's shocking collapse? |
The Motley Fool
September 25, 2009
Brian Orelli |
Dendreon Struts Its Stuff Like a peacock without any FDA-approved feathers. |
The Motley Fool
August 5, 2011
Brian Orelli |
Still Want to Be the Next Dendreon? The biotech market is punished. |
The Motley Fool
August 31, 2010
Brian Orelli |
What Is Dendreon Worth? Now that's a good question, isn't it? |
The Motley Fool
April 30, 2010
Brian Orelli |
Pricey Provenge Pumps Up Dendreon Dendreon's prostate cancer drug is approved, but at what cost, and will insurance pay for it? |
The Motley Fool
December 16, 2011
Brian Orelli |
Dendreon 2011: Supply Constrained to Missed Guidance A year in review for the biotech. |
The Motley Fool
March 13, 2008
Brian Lawler |
Dendreon Rolls the Dice The pharmaceutical amends a phase 3 study on its lead prostate cancer drug. |
The Motley Fool
March 2, 2011
Brian Orelli |
When Will Dendreon Make Money? Not for awhile ... it's a biotech thing. |
The Motley Fool
March 14, 2007
Dan Bloom |
National Semiconductor's Gross Improvement Gross margins at National Semiconductor are much stronger than they were a couple of years ago. Are these shares a buy? |
The Motley Fool
February 15, 2008
Brian Lawler |
Dendreon's Not-So-New Data Development-stage drugmaker Dendreon releases "new data" on lead cancer drug Provenge; unfortunately, the data wasn't the data that investors are waiting for. |
The Motley Fool
May 3, 2011
Brian Orelli |
Brakes Are Off at Dendreon Ramping up sales, one month at a time. |
The Motley Fool
May 10, 2006
Brian Lawler |
Dendreon Drives On Will the FDA say yes to a new cancer drug? Investors, take note. |
The Motley Fool
January 5, 2012
David Williamson |
Dendreon Investors: Why Shares Are Soaring Tripling Provenge sales causes shares to soar 50%. |
The Motley Fool
August 18, 2010
Travers & Greer |
Dendreon's Big Pharma Future Dendreon has had success with its prostate cancer treatment Provenge. What does Provenge's success mean for the future of Dendreon? |
The Motley Fool
August 10, 2011
Jim Mueller |
Rising Star Buy: Digging Dendreon After getting hammered, there's an opportunity here. |
BusinessWeek
October 6, 2003
Gene G. Marcial |
Dendreon: New Weapons against Tumors What's so hot about Dendreon, which leaped from 3 last year to 9.25 on Sept. 24? The little-known biotech develops immunologically based cancer remedies, and its lead product, Provenge, is aimed at prostate cancer. |
The Motley Fool
November 23, 2011
Brian Orelli |
I Was Wrong About Dendreon But maybe not in the long term. |
The Motley Fool
August 17, 2007
Rich Smith |
Foolish Forecast: Analog Needs a Bump In advance of earnings reports, Analog Devices hopes to make it three quarters in a row of beating estimates; analysts think it is a long-shot at best. |
The Motley Fool
August 29, 2011
Brian Orelli |
We Can Make More! Too Bad Few Want It Dendreon is no longer constrained by its supply. |
The Motley Fool
January 20, 2004
Dave Marino-Nachison |
Dendreon Calls for Cash Investors don't mind a secondary offering when it comes on the coattails of good news. |
The Motley Fool
November 16, 2007
Brian Lawler |
Waiting on a Friend for Dendreon Dendreon looks for a marketing partner for a prostate cancer drug that's in clinical trials. Investors, take note. |
The Motley Fool
January 17, 2007
Brian Lawler |
Dendreon in the Fast Lane The FDA speeds up review of Dendreon's leading drug candidate. Investors, take note. |
The Motley Fool
June 19, 2009
Brian Orelli |
Dendreon Is No Dot-Com Story ... Yet Is Dendreon a bad buy at today's prices? Not if it gets cancer treatment Provenge approved. And there's the risk. |
The Motley Fool
November 30, 2011
David Williamson |
Health Care's 5 Worst November Flops These stocks had a terrible month. |
The Motley Fool
April 5, 2010
Brian Orelli |
1 Month to Go! Is Dendreon a Buy? Only if you understand the risks. |
The Motley Fool
June 30, 2011
Brian Orelli |
Dendreon Increases Potential Output, More to Come Los Angeles plant is approved. |
The Motley Fool
October 27, 2006 |
MedImmune Gets Its Shots: Fool by Numbers The biotech released third-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... |
The Motley Fool
June 1, 2007
Brian Lawler |
Dendreon Gains. Why? Shares of the biopharma rise after it announces already expected news. |
The Motley Fool
January 7, 2011
Brian Orelli |
Dendreon Heads Across the Pond A pathway to Provenge approval in the EU. |
The Motley Fool
June 1, 2010
Brian Orelli |
Save Your Money, Dendreon As much as doctors would like to prescribe Dendreon's Provenge for their patients, manufacturing limitations will keep demand outpacing supply for awhile. |
The Motley Fool
November 25, 2011
Brian Orelli |
7 Black Friday Biotech Bargains Get in at the right time to maximize your returns. |
The Motley Fool
October 21, 2005
Seth Jayson |
SanDisk's Slam Dunk: Fool by Numbers The leading flash-memory maker released third-quarter 2005 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
August 4, 2010
Brian Orelli |
Dendreon Doubles Up The biotech enjoys twice as much revenue month over month. |
The Motley Fool
May 10, 2005
Charly Travers |
Dendreon in the Spotlight The small biotech's prostate cancer drug is in phase 3 development. Is this company worth investing in? |
The Motley Fool
January 10, 2012
Brian Orelli |
Linear Growth Isn't Enough Human Genome Sciences needs to accelerate growth. |
The Motley Fool
August 9, 2010
Brian Orelli |
Dendreon's in Trouble Provided you call a slap on the wrist from the FDA "trouble." |
The Motley Fool
December 13, 2007
Rich Smith |
Foolish Forecast: Value Line's Punchline In advance of earnings reports from Value Line, lets take a look at the company's last two quarters. |
The Motley Fool
April 20, 2006
Tim Beyers |
Apple Crunches Q2 Estimates: Fool by Numbers Apple Computer released second-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
August 11, 2011
Brian Orelli |
Dendreon's a Broken IPO, Again $10 isn't really a magical number. |
The Motley Fool
November 17, 2006 |
Big Lots Beats the Bets: Fool by Numbers The discount retailer released third-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
November 15, 2005
Seth Jayson |
Fool by Numbers: American Eagle Gains Altitude The clothing retailer released third-quarter 2005 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
September 13, 2011
Brian Orelli |
Drug Launches: It's All About Expectations Optimer jumps on measly sales. |
The Motley Fool
April 29, 2009
Brian Orelli |
2 Lessons From Dendreon Traders beware. |
The Motley Fool
April 14, 2009
Brian Orelli |
Sell Dendreon! No, Buy Dendreon! Dendreon, everyone's favorite tiny biotech, just got bigger because of positive phase 3 results for its prostate cancer treatment, Provenge. |
The Motley Fool
November 4, 2010
Brian Orelli |
Are Monthly Numbers Necessary, Dendreon? Focus on what's important. |
The Motley Fool
March 11, 2011
Brian Orelli |
Sales Can Quadruple, More to Come Dendreon is still supply-constrained, but less than before. |
The Motley Fool
November 10, 2006 |
Big 5 Sporting Goods: Fool by Numbers The retailer released third-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
December 19, 2006
David Meier |
Golf Galaxy's Coming Up 18: Fool by Numbers The golfing retailer released its third-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
